Jabil Inc vs Revvity Inc — how do they compare? Jabil Inc trades at $303.68 (market cap $31.35B), while Revvity Inc trades at $154.33 (market cap $16.98B). The key difference: Jabil Inc is the larger of the two by market cap, and Revvity Inc pays the higher dividend (0.18%). Which is the better fit depends on your goals — on Pluang, investors hold Jabil Inc for 23 Days and Revvity Inc for 12 Days on average.
| JBL | RVTY | |
|---|---|---|
Market Cap | $31.35B | $16.98B |
Volume | 1,337,978 | 1,456,900 |
Sector | Technology | Health |
52-Week High | $385.50 | $157.36 |
52-Week Low | $192.49 | $82.26 |
Typical Hold Time | 23 Days | 12 Days |
Enterprise Value | $33.63B | $19.30B |
Dividend Yield | 0.11% | 0.18% |
Signals from Pluang's Aura AI — not financial advice
JBL trades at $301.76, up 0.76% today, with a bearish technical signal despite strong earnings beats in recent quarters. The stock shows robust fundamentals with revenue growth to $29.80B in 2025 and a high ROE of 74.11%, though net margins are thin at 2.9%. AI infrastructure demand is driving optimistic fiscal 2027 guidance, with a consensus analyst price target of $434.75 implying significant upside.
The outlook is positive due to accelerating AI-led growth and strong analyst support, but risks include market volatility post-earnings and high valuation multiples. Investment appeal hinges on execution of projected 24% revenue growth, while current technical weakness may present a buying opportunity for long-term investors.
Revvity (RVTY) trades at $154.33, up 0.48% on the day and near its 52-week high of $158.28. The stock exhibits a bullish technical trend with strong moving average signals, while recent earnings beats and positive analyst upgrades reflect solid fundamentals. Key developments include the launch of a new Type 1 diabetes screening kit in Europe and the acquisition of Human Cell Design to bolster metabolic disease research, signaling growth in diagnostics and life sciences.
The outlook remains positive given consistent earnings outperformance and strategic expansions, though rich valuation multiples pose a risk if growth moderates. Investors face near-term headwinds from margin pressures in China and elevated P/E ratios, but institutional accumulation and a lack of sell ratings support a constructive bias for long-term holders.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Jabil is a global manufacturing solutions provider for industries including healthcare, automotive, and cloud. It offers comprehensive design, engineering, and supply chain management for complex electronic products.
Read more on JBL →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →